Compare PCT & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | KALV |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | 174 | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 955.4M | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | PCT | KALV |
|---|---|---|
| Price | $12.00 | $26.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $13.00 | ★ $32.60 |
| AVG Volume (30 Days) | 3.7M | ★ 4.4M |
| Earning Date | 05-06-2026 | 07-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | $380.44 | $185.42 |
| Revenue Next Year | $203.33 | $59.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $4.93 | $9.83 |
| 52 Week High | $17.37 | $26.85 |
| Indicator | PCT | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 85.92 | 75.07 |
| Support Level | $7.87 | $14.66 |
| Resistance Level | $12.31 | N/A |
| Average True Range (ATR) | 0.69 | 0.25 |
| MACD | 0.38 | 0.08 |
| Stochastic Oscillator | 84.60 | 98.86 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.